Prostate cancer is the most common noncutaneous cancer among men.
This case report describes a 43-year-old man with rapidly progressing castration-resistant prostate cancer (CRPC) that responded initially to docetaxel and did not tolerate cabazitaxel. He subsequently received a third line of chemotherapy with cyclophosphamide and prednisone, and experienced a dramatic clinical and radiographic response in his liver metastases. This therapeutic intervention led to a significant clinical benefit and confirms the potential use of cyclophosphamide in patients with CRPC, particularly those with liver metastases.
Written by:
Batty N, Yarlagadda N, Pili R. Are you the author?
Department of Medicine, Roswell Park Cancer Center, Buffalo, New York.
Reference: J Natl Compr Canc Netw. 2013 Aug 1;11(8):911-5.
PubMed Abstract
PMID: 23946170
UroToday.com mCRPC Treatment Section
